Continued growth “despite Covid-19”

AFT Pharmaceuticals has announced growth across its portfolio of OTC and prescription medicines in its half-year financial results AFT Pharmaceuticals reports “continuing good progress” in commercialising its Maxigesic pain medication in international markets, despite Covid-19 challenges. Group operating revenue for the six months to 30 September 2020 grew by 4% to NZ$48.8 million from NZ$46.9